Avacopan: Is it the end of the road? | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evaluation of the long-term safety of avacopan in ANCA-associated vasculitis: Design of the real-world AvacoStar study (Preprint)2025
2POS0223 REAL WORLD USE AND OUTCOMES OF AVACOPAN FOR ANCA-ASSOCIATED VASCULITIS DIFFER FROM CLINICAL TRIALS: A MULTICENTRE UK COHORT STUDY2024 · 2 citations
3AB1245 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS RECEIVED INTENSIFIED INDUCTION THERAPY WITH CYCLOPHOSPHAMIDE PLUS RITUXIMAB – RETROSPECTIVE OBSERVATION TWO-CENTRE STUDY OF 30 PATIENTS2024
4AB1261 AVACOPAN IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS: MULTICENTER PROSPECTIVE REAL-LIFE STUDY ON EFFICACY, SAFETY, AND IMPACT ON QUALITY OF LIFE2024 · 1 citations
5Avacopan-Associated Hepatotoxicity: Clinical Signal, Liver Injury Patterns, and Plausible MechanismsHuman Clinical Trial · 2026 · 1 citations

More from Clinical Kidney Journal

More from Karolinska Institutet